Note regarding MiFID II: This research report has been prepared by order of the issuer based on a contractual agreement and is being compensated for by the issuer. The research report has simultaneously been made publicly available to all interested persons. Hence, the receipt of this research report is to be regarded as a permitted insignificant non-monetary benefit according to § 64 para 7 sentence 2 No. 1 and 2 of the German Securities Trading Act (WpHG). Frequentis AG's (ISIN ATFREQUENT09, ...
MiFID II – Hinweis: Diese Studie wurde auf Grundlage einer vertraglichen Vereinbarung im Auftrag des Emittenten erstellt und von diesem vergütet. Die Studie wurde gleichzeitig allen Interessenten öffentlich zugänglich gemacht. Der Erhalt dieser Studie gilt somit als zulässiger geringfügiger nichtmonetärer Vorteil im Sinne des § 64 Abs. 7 Satz 2 Nr. 1 und 2 des WpHG. Die 2023er Geschäftszahlen der Frequentis AG (ISIN ATFREQUENT09, General Standard, FQT GY) überzeugen - vor allem bei Auftragsein...
>2023 sales up 11% to € 427m, and EBIT margin at 6.1% in line with the guidance - Frequentis reported yesterday its FY 2023 earnings, which were in line with our expectations. Revenues were up by 10.7% y-o-y at € 427.3m (vs ODDO BHF € 425.3m, +10.1%). This achievement was driven mainly by the ATM divisions: The ATM segment (69% of group sales) grew by 13.6% y-o-y to € 311m, and the PST division (31% of group sales) posted growth of 5% to € 139m. This good outcome is ...
>2023 sales up 11% to € 427m, and EBIT margin at 6.1% in line with the guidance - Frequentis reported yesterday its FY 2023 earnings, which were in line with our expectations. Revenues were up by 10.7% y-o-y at € 427.3m (vs ODDO BHF € 425.3m, +10.1%). This achievement was driven mainly by the ATM divisions: The ATM segment (69% of group sales) grew by 13.6% y-o-y to € 311m, and the PST division (31% of group sales) posted growth of 5% to € 139m. This good outcome is ...
>Croissance T2 flat à cc, légèrement inférieure aux attentes - Accenture a publié hier avant l’ouverture de la Bourse US, ses résultats T2 2024 (trimestre clos à fin février). La croissance ressort flat y/y à cc, en ligne avec le milieu de fourchette de sa guidance (-2% à 2% y/y à cc) mais légèrement en-dessous des attentes (+0.7% y/y à cc). Il s'agit d'un nouveau ralentissement par rapport au T1 2024 (+1% à cc). Ce ralentissement est notamment lié au déclin des acti...
>Q2 growth flat at cc, a shade below forecasts - Yesterday before trading started on the US market, Accenture reported its Q2 2024 earnings (quarter to end-February). Growth was flat y-o-y at constant currency, in line with the middle of the guidance range (-2% to 2% y-o-y at cc) but a shade below forecasts (+0.7% y-o-y at cc). This was a fresh slowdown relative to Q1 2024 (+1% at cc). This slowdown is due notably to the downturn in the operations activities, with a ...
>Organic growth Q1 of +1% cc, a shade above expectations - Accenture reported its Q1 2023-24 results (quarter closed on 30 November) before the start of trade on the US stock market. Growth was 1% y-o-y at constant currency (cc), slightly above the middle of the guidance range (-2% to 2% y-o-y at cc) and in line with forecasts (+0% y-o-y at cc). This marks another slowdown vs Q4 2022-2023 (+4% at cc). This slowdown is mainly due to the fall-off in activity in Operatio...
>Croissance org. T1 de +1% cc, légèrement supérieure aux attentes - Accenture a publié hier avant l’ouverture de la Bourse US, ses résultats T1 2023/2024 (trimestre clos à fin novembre). La croissance ressort à 1% y/y à cc, légèrement au-dessus du milieu de fourchette de la guidance (-2% à 2% y/y à cc) et des attentes (+0% y/y à cc). Il s'agit d'un nouveau ralentissement par rapport au T4 2022/2023 (+4% à cc). Ce ralentissement est principalement lié au coup d’arrêt d...
We reiterate our Neutral rating, price target to €0.80 per share. The material additional investment requirements for Accoya USA caught us by surprise. The proceeds of the share issue and the convertible loan plus the amendment of the RCF and term loan ensure that the Accoya USA plant can be completed (>80% done) and that sufficient sales and marketing power can be applied to develop demand in the US to ensure that sales match the envisaged output. In a scenario where demand in Europe...
We reiterate our Neutral rating, price target to €0.80 per share. The material additional investment requirements for Accoya USA caught us by surprise. The proceeds of the share issue and the convertible loan plus the amendment of the RCF and term loan ensure that the Accoya USA plant can be completed (>80% done) and that sufficient sales and marketing power can be applied to develop demand in the US to ensure that sales match the envisaged output. In a scenario where demand in Europe...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.